IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
Rhea-AI Summary
IDEAYA Biosciences (NASDAQ: IDYA) announced management will participate in investor events the week of December 2, 2025.
Management appearances include a fireside chat with CEO Yujiro S. Hata at Citi's 2025 Global Healthcare Conference on Dec 2, 2025 at 9:00 AM ET and a fireside chat with CEO Yujiro S. Hata at the 8th Annual Evercore Healthcare Conference on Dec 3, 2025 at 10:50 AM ET.
A live audio webcast will be available via the IDEAYA Investors/Events webpage or through the conference host where permitted, with webcasts replayable for 30 days after the live event.
Positive
- None.
Negative
- None.
News Market Reaction – IDYA
On the day this news was published, IDYA gained 2.00%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Citi's 2025 Global Healthcare Conference
Tuesday, December 2nd, 2025 at 9:00 AM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
8th Annual Evercore Healthcare Conference
Wednesday, December 3rd, 2025 at 10:50 AM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Jonathan Miller, Managing Director, Biotech and Pharma Equity Research
A live audio webcast of the conference events, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-december-2025-investor-relations-events-302623457.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When will IDEAYA (IDYA) present at Citi's 2025 Global Healthcare Conference?
What time is IDEAYA (IDYA) scheduled at the Evercore Healthcare Conference on December 3, 2025?
How can investors listen to IDEAYA (IDYA) conference webcasts for December 2025 events?
Will IDEAYA (IDYA) conference webcasts be available after the live events?
Who will host the IDEAYA (IDYA) fireside chats at the December 2025 conferences?
